| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Biotechnology (IBB) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Biotechnology sector is positive (overall 1.9, positive 3.4, negative -1.5) on 20251028. The forces of Broad Market Trend (0.9), Option Speculation (0.75), Sector Price Trend (0.6), Sentiment towards Fundamentals (0.6), and Market Risk Prefrence (0.5) will drive up the price. The forces of Price Level (-0.5), and Valuation Sentiment (-1) will drive down the price. The swing to upside will be significant considering the high positive sentiment forces (3.4). The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on IBB trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Market Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-28 | 0% | 0.3% | 157.66 | 96 | 0.35% | 0.39% | 0.6 | 1.9 | 0.6 | 7.7 |
| 2025-10-27 | 1% | 0.3% | 157.11 | 90 | 1.26% | 0.45% | 1.6 | 1.6 | -0.5 | 4 |
| 2025-10-26 | 1% | 0.1% | 0.4 | -0 | 0 | 7 | ||||
| 2025-10-25 | 0% | 0% | 0.4 | 0.1 | 0.1 | 0 | ||||
| 2025-10-24 | 0% | 0% | 155.16 | 76 | 0.38% | 0.33% | 0.4 | 0.1 | 0.1 | 7 |
| 2025-10-23 | 0% | 0% | 154.58 | 73 | 0.43% | 0.13% | 0.2 | 0.1 | 0.3 | 0 |
| 2025-10-22 | 0% | 0% | 153.92 | 71 | -1.35% | 0.13% | 0.2 | -0.6 | 0.5 | 7 |
| 2025-10-21 | 0% | 0% | 156.03 | 84 | -0.29% | 0.39% | 1 | 1.6 | 1.5 | 0 |
| 2025-10-20 | 0% | 0% | 156.49 | 90 | 1.49% | 0.4% | 1.6 | 2.8 | 2.7 | 7 |
| 2025-10-19 | 0% | 0% | 1.3 | 3.4 | 3 | 0 | ||||
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| IBB Behaviors |
| ● Biotechnology (30%): The directional probability for IBB is 20% from last trading session on Mon. Oct 27, 2025. Both emotion level 6.7 is much higher than sentiment level 0.1 on Tue. Oct 28, 2025. Biotechnology (IBB) is attracting noticeable market attention on Tue. Oct 28, 2025. IBB is likely to move higher on any positive news, and recover from any dips of negative news. When the price move is against the technical setup, sentiment and emotion, it's a sign of trend reversal. |
| 1 (8) Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments Shares of Cytokinetics, which targets medicines for specialty heart diseases, have jumped about 69% over the past three months and are up 31% year to date. (https://www.cnbc.com/) Tue. Oct 28, 2025 | |
| 2 (7) Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook. (https://www.benzinga.com/) Tue. Oct 28, 2025 | |
| 3 (8) Nvidia says Eli Lilly will purchase more than 1,000 GPUs to power drug discovery efforts Nvidia announced on Tuesday that drugmaker Lilly is developing an AI system using more than 1,000 Blackwell Ultra chips. (https://finance.yahoo.com/) Tue. Oct 28, 2025 | |
| 4 (8) Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday Novartis is buying Avidity Biosciences in an all-cash deal valued at $12 billion to access Avidity's experimental treatments for neuromuscular diseases. (https://finance.yahoo.com/) Mon. Oct 27, 2025 | |
| 5 (-7) Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event. (https://www.benzinga.com/) Mon. Oct 27, 2025 | |
| 6 (7) Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030 Vertex appears to be by far the better buy right now. (https://www.fool.com/) Mon. Oct 27, 2025 | |
| 7 (8) Novartis to acquire Avidity Biosciences for about $12 billion (Fixes timeframe in last paragraph to "In July") By Padmanabhan Ananthan and Angela Christy M (Reuters) -Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity (https://finance.yahoo.com/) Mon. Oct 27, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA